Bleomycin Sulfate

Catalog No.S1214 Synonyms: NSC125066

Bleomycin Sulfate Chemical Structure

Molecular Weight(MW): 1512.62

Bleomycin Sulfate is a glycopeptide antibiotic and an anticancer agent for squamous cell carcinomas (SCC) with IC50 of 4 nM in UT-SCC-19A cells.

Size Price Stock Quantity  
USD 170 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Bleomycin Sulfate is a glycopeptide antibiotic and an anticancer agent for squamous cell carcinomas (SCC) with IC50 of 4 nM in UT-SCC-19A cells.
In vitro

UT-SCC-12A and UT-SCC-12B are both more resistant to Bleomycin sulfate with IC50 of 14.2 nM and 13 nM, respectively. [1] Alveolar macrophages incubated with 0.01 μg/mL to 1μg /mL Bleomycin sulfate for 18 hours secretes significantly more fibroblast growth factor than macrophages incubated without Bleomycin sulfate. Macrophages stimulated with Bleomycin sulfate continues to produce significant amounts of fibroblast growth factor even after Bleomycin sulfate is removed and replaced with fresh (Bleomycin sulfate-free) media. Fibroblast growth factor secretion by Bleomycin sulfate-stimulated alveolar macrophages is inhibited by cycloheximide, and the 5-lipoxygenase inhibitors NDGA (nordihydroguaiaretic acid) and BW755c, indicating not only a requirement for protein synthesis but also for metabolites of the 5-lipoxygenase pathway of arachidonic acid metabolism for full expression of activity. [2] Bleomycin sulfate (400 µg/mL) incubation for 24 hours decreases the viability of NTera-2 cells, and increases caspase-3, -8 and -9 activities, Bax and cytoplasmic cytochrome c levels and decreases Bcl-2 levels. [3] In terms of unstable aberrations, the clastogenic effect of Bleomycin sulfate on ADIPO-P2 cells persists for at least 10 days after exposure. Bleomycin sulfate-induced telomere instability in mammalian cells persists for several generations after exposure. Moreover, the appearance of telomere fusions in Bleomycin sulfate-exposed cells 10 days after treatment suggests that Bleomycin sulfate can induce delayed telomere instability. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
F98 NGDWTGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlmzNQKBmzFyMECg{txu MWmyOEBpyqB? Mmr2bY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> MVmyOlA5QDdzMR?=
POLK WT MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vmVGlEPTB;MUGuO-KBkcLz4pEJNU44yqEQvF2= MVuyOlA{OTRyMB?=
POLK KO MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPqd5pKSzVyPUSuNFPjiIoEsfMAjVEvQTMEoN88US=> M1;MNVI3ODNzNECw
POLK CD MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTVwNUpihKnDueLCiUGuNFDDqM7:TR?= NILT[YszPjB|MUSwNC=>
RLE/Abca3 MXTGeY5kfGmxbjDBd5NigQ>? MUWwMlTDqM7:TR?= NXKz[HlPOTR2wrDo MXLpcoR2[2W|IHGgcY9zeGixbH;nbYNidCClaHHu[4Uh\nKxbTDldIl1cGWuaXHsMYxqc2VibX;ydIhwdG:peTD0c{BiKHerZHWsJJNxemWjZD3veZQhdW:{cHjvcI9ogcLi NX\ZfFlYOjV5NkC1N|g>
PMCs MVnGeY5kfGmxbjDBd5NigQ>? Mni0NE4y6oDVMtMg{txoN22u M4njPVI1yqCq M3[0V4NifXOnczDhJIRwe2VvZHXw[Y5l\W62IHnuZ5Jm[XOnIHnuJJRp\SCycn;0[YlvKGyndnXsJI9nKGOxbHzh[4VvNUoEoB?= NYLPdoJ1OjV3OUW2OFI>
PMCs Mn\RSpVv[3Srb36gRZN{[Xl? NHfHO3UxNjMEoN88[{9udA>? NYPiXJM{OjUkgKO3NuKhcA>? M4nKbIlv\HWlZYOgbY5kemWjc3XzJIlvKH[rbXXueIlvKGGwZDFOtU1UVUFicILveIVqdg>? Ml73NlU2QTV4NEK=
PMCs NX[5UnJYTnWwY4Tpc44hSXO|YYm= NIHQXlUxNjMEoN88[{9udA>? M4PxSFczKGh? NIjSR4RqdmS3Y3XzJIRm[3KnYYPld{BqdiCleYTvb4Vz[XSrbj24JIFv\CCHLXPh[IhmemmwIIDyc5RmcW5? NETaWYQzPTV7NU[0Ni=>
PMCs MmK0SpVv[3Srb36gRZN{[Xl? NWrTellLOC5{wrFOwIcwdWx? NUP0NWxPOTJxMkSvOFghcA>? NVrxc|JZcW6lcnXhd4V{KGOnbHygcYloemG2aX;u NXKySlZ[OjV3OUW2OFI>
IMR-32 NITWcHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfVeGlIPy534pkSNVIxKML3Zz;tcC=> NWqwRoFCOTMkiKK0PEBp MVnJR|UxRTZyINM1[{9udCCjdDD0bIUh\W6mIH;mJFI1KGi{czDv[kBqdmO3YnH0bY9v MljQNlU2OzZ|NEW=
HT1080 NGPrVHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfS[IpEOSEQvF2= M{ToV|I1KGkEoB?= MlTrcIVi\HNidH:gZUBIOi:PIHTlcIF6 MkXvNlU2OTh7NkG=
HT1080 Mn31SpVv[3Srb36gRZN{[Xl? MmLrNUDPxE1? NGDifIgzPCCqwrC= NXXQPVNZcW6mdXPld{BiKHCxdHXueEBodG:kYXygSG5CKGSjbXHn[UBz\XOyb37z[S=> M3PPTFI2PTF6OU[x
HDFn MUnDfZRwfG:6aXPpeJkhSXO|YYm= Ml2wO|IhcA>? NIrNNndKSzVyPUmuN|EmyqB? MlnnNlUzPzZ5OUK=
THP-1 MmHjR5l1d3SxeHnjbZR6KEG|c3H5 NHjLUZM4OiCq MYXJR|UxRTRwN{el M4jPclI2Ojd4N{my
HT-29 MmXTR5l1d3SxeHnjbZR6KEG|c3H5 MV23NkBp NIi4RYxKSzVyPUGxMlQ6LQ>? MkC5NlUzPzZ5OUK=
HCT116  NGHjRmhEgXSxdH;4bYNqfHliQYPzZZk> NXvNPGI{PzJiaB?= NF34SFhKSzVyPUGxMlM1LQ>? MYOyOVI4Pjd7Mh?=
A431 M3nVXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2qyeVUxNTJyMDDJWS=> MYO0PQKBkWh? Mlv4bY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> MoO0NlUyODF{OUm=
T24 MkXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;yZllSPTBvMkCwJGlW NU\LSmVjPDkkgJno MnzPbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> NFXDT3QzPTFyMUK5PS=>
AY-27  NEnYc5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWO1NE0zODBiSWW= M3PkZlQ56oDLaB?= NXzJOo85cW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? MkPLNlUyODF{OUm=
A549 Mn\zSpVv[3Srb36gRZN{[Xl? MYKxJOK2\y:vTNMg Ml3nNE01QCCq NITVT|VqdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4bDqE:STtMgcXJPSQ>? M4P6WVI1QTZ|NkO1
MLE12 M3XremZ2dmO2aX;uJGF{e2G7 M{\iT|EhyrWpL33MxsA> M1HUNlAuPDhiaB?= MmOybY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mxsBQWE8EoH3SUmE> MWOyOFk3OzZ|NR?=
Jurkat MnLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXMNlDjiIoQvH2= NFLPOmszPOLCiXlCpC=> NXfob|Y5[XK{ZYP0d{B1cGViY3XscEBkgWOuZTDheEB1cGViR{KgdIhie2V? MmDPNlQ6OTZ6OUO=
HeLa  NWLlfnNiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoGxTWM2OD1zMD6yxsDPxE1? M4L4[lI1PzN{M{m3
C18-4 MnvCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\OV2J[OC1zMECg{txO Mn;ZbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> MnTYNlQ2PzF7OEK=
BMG-1  NX;yOJB4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PpblQxNzhywrFOwIcwdQ>? M{jhRVPDqGh? NGj5dVdqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 MXqyN|kxPjd{Nh?=
A459 M3\VSGFxd3C2b4Ppd{BCe3OjeR?= M{jYbFExKG2X NXfJeZBZPDhiaB?= MnPNbY5lfWOnczDhdI9xfG:|aYO= M3\SNVI{QTB{N{[2
MOCK NGfOPHZCeG:ydH;zbZMhSXO|YYm= MXyxNEBuXQ>? Mm[2OFghcA>? NXrsNXAxcW6mdXPld{BieG:ydH;zbZM> NH33[WkzOzlyMke2Oi=>
MMP1 MlnuRZBweHSxc3nzJGF{e2G7 M4rkNlExKG2X MVi0PEBp NGXOT2JqdmS3Y3XzJIFxd3C2b4Ppdy=> M1PNcVI{QTB{N{[2
A549 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;uNlAxKM7:TR?= MXOyOEBpyqB? NXr0OIRj\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JJNq\26rZnnjZY51dHl? NWDUcoxNOjN6MEW3PVM>
HCT-116 MX;BdI9xfG:|aYOgRZN{[Xl? Mon6N{84NjVxMUWg{txoN22u NFLZfGM1QCCq NFvuPZJz\WS3Y3XzJJRp\SCuZY\lcEBw\iCETFigZZQhcGmpaDDjc45k\W62cnH0bY9v MY[yN|cxQDZ4OB?=
HeLa MYXBdI9xfG:|aYOgRZN{[Xl? Ml23N{84NjVxMUWg{txoN22u NW\ROJFjPDhiaB?= M{O1UpJm\HWlZYOgeIhmKGyndnXsJI9nKEKOSDDheEBpcWeqIHPvcoNmdnS{YYTpc44> MoO0NlM4ODh4Nki=
HCT116 NEm1SYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEm4V3cxNTFyMDFOwIcwdWx? MnfEOFghcA>? M4XqUolvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> MkHXNlM2OTh{MEG=
NCM460 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XkW|AuOTByIN88[{9udA>? NUKzc|ZZPDhiaB?= MWfpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 NGOyd5gzOzVzOEKwNS=>
NT2  Mn\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPrNlQhcMLi MlHwUGQ2OD12MEFihKnDvWdxbXy= MYqyN|M5PjR{MB?=
NT2  NX7hVHkyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1joU|Q5KGh? NVTkUpNvVER3ME2xNFAhyrWpL33s MYSyN|M5PjR{MB?=
NT2  M1rJNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjrcZFXPzJiaB?= NFjTc3pNTDVyPUKw5qCKyrWpL33s M4rxWVI{Ozh4NEKw
NT2  NVPnPJdrSXCxcITvd4l{KEG|c3H5 MmH4OFAx6oDLwsXnM41t NXLoeZJIOjRiaNMg NWT3NZUycW6mdXPld{B{cWewaX\pZ4FvfCCrbnPy[YF{\XNiaX6gZ4F{eGG|ZT2zMFgtQSCjY4Tpeol1gcLi MkjxNlM{QDZ2MkC=
NTera-2 MYPGeY5kfGmxbjDBd5NigQ>? MVyxNlAh|rypL33s MYm3NkBp NH;JRWR{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczC4MYl{d3C{b4P0ZY5mKGyndnXsdy=> MnXsNlI5OjV|NUW=
NCCIT NYjRcnpOTnWwY4Tpc44hSXO|YYm= NEjGUpgyOjBizsznM41t NUD3WlJGPzJiaB?= MlvEd4lodmmoaXPhcpRtgSCrbnPy[YF{\XNiOD3pd49xem:|dHHu[UBt\X[nbIO= MYqyNlgzPTN3NR?=
NTera-2 MVzGeY5kfGmxbjDBd5NigQ>? M1TJdlEzOCEQvHevcYw> NF;ZeXM4OiCq MX7zbYdvcW[rY3HueIx6KGmwY4LlZZNmeyCWQlHSV{Bt\X[nbIO= M33VS|IzQDJ3M{W1
NCCIT MX;GeY5kfGmxbjDBd5NigQ>? NX\QSWs3OTJyIN88[{9udA>? NYrlXI5rPzJiaB?= NGjzbYV{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczDURmFTWyCuZY\lcJM> MlrVNlI5OjV|NUW=
NCCIT NY[3b3BuTnWwY4Tpc44hSXO|YYm= NGXlOZoyOjBizsznM41t M3OxZVczKGh? NVPGfIV4e2mpbnnmbYNidnSueTDk[YNz\WG|ZYOgS3NJKGyndnXsdy=> MlPINlI5OjV|NUW=
NTera-2 M{LsRWZ2dmO2aX;uJGF{e2G7 NXjXVGN[OTJyIN88[{9udA>? NF31[5k4OiCq NWS4do5We2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgVJJwfGWrbjDjZZJjd267bDDs[ZZmdHN? MWWyNlgzPTN3NR?=
NCCIT MlXzSpVv[3Srb36gRZN{[Xl? M2LhPVEzOCEQvHevcYw> MnXOO|IhcA>? MkD4d4lodmmoaXPhcpRtgSCrbnPy[YF{\XNiUILveIVqdiClYYLic456dCCuZY\lcJM> MkeyNlI5OjV|NUW=
NTera-2 M{TBfWZ2dmO2aX;uJGF{e2G7 MmLSNVIxKM7:Zz;tcC=> MWC3NkBp NXLSS2Uze2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgUHBQKGyndnXsdy=> MV[yNlgzPTN3NR?=
NCCIT M1ni[WZ2dmO2aX;uJGF{e2G7 NVT6OGZQOTJyIN88[{9udA>? MYm3NkBp NEnEZ4N{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczDMVG8hdGW4ZXzz MYKyNlgzPTN3NR?=
MDA-MB-468 NXn5[IpuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfhbmgx6oDVMkCwxsDPxGdxbVy= NEm2eJAzPCCq MUnpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 NHy2W|AzOjhzOUG5Oi=>
231-H2N MmfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlWxNQKBmzJyMNMg{txoN22O M3SyOlI1KGh? MkfDbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> M4nSO|IzQDF7MUm2
A549  MXXGeY5kfGmxbjDBd5NigQ>? MVOyNFAwPDByIN88US=> M4HBSJJme3WudIOgbY4h[SCmb4PlMZJme3CxboPpeoUhcW6lcnXhd4UhcW5iUl;T NVrpe2txOjJ5N{O2PVc>
A549  MmHlSpVv[3Srb36gRZN{[Xl? M3ThcVAuPDByIN88US=> M3THNFIuPDhiaB?= M4DaV4NifXOnczDtc5JmKG22RF7BJJRp[W5iblTORUBl[W2jZ3W= NEHUNVkzOjd5M{[5Oy=>
A549  MUPGeY5kfGmxbjDBd5NigQ>? NXjGWlJYOTByIN88UeKh NF7WcYsx6oDVNEigbC=> NUn2XoVH[2G3c3XzJINie3Cjc3WtN{Bi[3SrdnH0bY9v NF;2V2gzOjd5M{[5Oy=>
A549  M{PtPWZ2dmO2aX;uJGF{e2G7 NFH1Wm0yODBizszNxsA> MnXENQKBmzR6IHi= NX\DWm9o[2G3c3XzJHBMTDFiY3zlZZZi\2V? MWOyNlc4OzZ7Nx?=
A549  M374cGZ2dmO2aX;uJGF{e2G7 NVHsdYZbOTByIN88UeKh M2izVlDjiJN2ODDo MYLjZZV{\XNibXn0c4Npd26mcnnhcEBtd2OjbHn6ZZRqd25ib3[gRoF5 NIe3cGszOjd5M{[5Oy=>
A549  NVuybnJTTnWwY4Tpc44hSXO|YYm= NHX4S|cyODBizszNxsA> NVTFWm0{OOLCk{S4JIg> M1W1Z4Rm[3KnYYPld{BOVVBiYX7kJGFVWCCuZY\lcJM> NH\HTYYzOjd5M{[5Oy=>
MCF-7/Her-18  MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUOwMlQzNTF5MECg{txoN22O M{PWXVI1KGh? NWrybHptcW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? MoX6NlI3OjF2MES=
MCF-7 Ml3xVGRVN1CFSTDUdoVifG2nboS= MoXRNE4zPSEQvHevcYwv MYGxMVQhcA>? MnnYd4hwf3Nic3nncolncWOjboSgLHDDqDxiMD6wOUkh[3m2b4TvfIlkKGWoZnXjeC=> MUGyNlU6OTJ6NB?=
MDA-MB-231 NWDpRoJPWESWL2DDTUBVemWjdH3lcpQ> MVywMlI2KM7:Zz;tcE4> M1z6WlEuPCCq M3TsRpNpd3e|IIPp[45q\mmlYX70JEhRyqB:IECuNFUqKGO7dH;0c5hq[yCnZn\lZ5Q> NWjnc4xjOjJ3OUGyPFQ>
MDA-MB-235  M1PqS3BFXC:SQ1mgWJJm[XSvZX70 MXqwMlI2KM7:Zz;tcE4> MWSxMVQhcA>? MVXzbI94eyC|aXfubYZq[2GwdDCoVOKhRCByLkC1LUBkgXSxdH;4bYMh\W[oZXP0 NEDoeJczOjV7MUK4OC=>
MCF-7 MlnsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYqwMVIh|rypL33sMi=> NX\pcIVDOjRxNEigbC=> NV;rbXdGTUN3ME2xMlIh|rypL33M MkHnNlI2QTF{OES=
NCCIT  NFTOPXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXOyUWJWOjEkgKOxOFDDqM7:Zz;tcC=> MmSzO|IhcA>? NVr5bWRwVER3ME2xNlDDqM7:Zz;tcOKh NXHaeXVmOjJ3NkKxOlA>
NCCIT  NEDqRXNHfW6ldHnvckBCe3OjeR?= MmL0O|IhcA>? MVrzbYdvcW[rY3HueIx6KGmwY4LlZZNmeyClYYPwZZNmNTNiYXP0bZZqfHoEoB?= MlLBNlI2PjJzNkC=
NCCIT  MYDGeY5kfGmxbjDBd5NigQ>? NHjrbpY4OiCq NU[ye3Yye2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgZ4F{eGG|ZT24JIFkfGm4aYT5xsA> MWGyNlU3OjF4MB?=
NCCIT  MlrrSpVv[3Srb36gRZN{[Xl? MnL2O|IhcA>? M3m4NpNq\26rZnnjZY51dHliaX7jdoVie2W|IHPhd5Bie2VvOTDhZ5Rqfmm2edMg MVWyNlU3OjF4MB?=
NCCIT  NX\qSGRNTnWwY4Tpc44hSXO|YYm= M{HpSFczKGh? M4TCeJNq\26rZnnjZY51dHliaX7jdoVie2W|IFLBXEBt\X[nbB?= M{O2e|IzPTZ{MU[w
NCCIT  NUHpTGZUTnWwY4Tpc44hSXO|YYm= NVfnW2c1PzJiaB?= M123OZNq\26rZnnjZY51dHliZHXjdoVie2W|IITo[UBD[2xvMjDjc451\W62 MnLXNlI2PjJzNkC=
NCCIT  M2\EPWZ2dmO2aX;uJGF{e2G7 MkT0O|IhcA>? MWLzbYdvcW[rY3HueIx6KGSnY4LlZZNmeyC2aHWgR5l1NWNibHX2[Yw> MkfSNlI2PjJzNkC=
HeLa NGfOeoRHfW6ldHnvckBCe3OjeR?= NFXpbmg{OC95MDFOwIcwdWx? NX[3dlAxOjUEoHi= MV\pcoNz\WG|ZYOgeIhmKG2UTlGgcIV3\Wy|IH;mxsBxPTQxvJzBWG0teDJzwrDhcoTDqEeDRFS0OS=> NIXLWXQzOjR6N{mzOy=>
MCF-7  NF\vbm1HfW6ldHnvckBCe3OjeR?= NHHnVJI{OC95MDFOwIcwdWx? M2\IU|I1yqCq NXrq[3NqcW6lcnXhd4V{KHSqZTDtVm5CKGyndnXsd{Bw\sLicEWz89yNSVSPLICyNeKh[W6mwrDHRWRFPDV? M1ntUVIzPDh5OUO3
HeLa NIruWVBEgXSxdH;4bYNqfHliQYPzZZk> M4DrbVMxNzdyIN88[{9udA>? NYq5O4UzOjUEoHi= NV;meJBmcW6mdXPld{BpcWeqbImgd4lodmmoaXPhcpQhdGW4ZXzzJI9nKG[{YXft[Y51\WRiRF7BJJJmdGWjc3WgbY51dyC2aHWgZ5l1d3CuYYPt NG\VdWozOjR6N{mzOy=>
MCF-7  NETYTYREgXSxdH;4bYNqfHliQYPzZZk> M{nQTVMxNzdyIN88[{9udA>? NUHNOZdVOjUEoHi= M{PzTYlv\HWlZYOgbIlocGy7IIPp[45q\mmlYX70JIxmfmWuczDv[kBnemGpbXXueIVlKESQQTDy[Yxm[XOnIHnueI8hfGinIHP5eI9xdGG|bR?= Mn6zNlI1QDd7M{e=
NT2 NEKwOGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfRNVAxNTZyMNMg{txoN22u NXrkVnVJOjRiaB?= Ml3hTWM2OD12MECgxtVoN22u NH3ke3IzOjR4OUm1Ni=>
NT2 MYrGeY5kfGmxbjDBd5NigQ>? NY\hPHVGPDBywrFOwIcwdWx? M2P0fFI1KGh? NETlXZN{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczDjZZNx[XOnLUOsPEw6KGGldHn2bZR6yqB? M33VVlIzPDZ7OUWy
NT2 NVnS[25HTnWwY4Tpc44hSXO|YYm= MWC0NFDDqM7:Zz;tcC=> NFzkUZQzPCCq MYLzbYdvcW[rY3HueIx6KGmwY4LlZZNmeyCEQWigcIV3\Wx? NU\PTm1rOjJ2Nkm5OVI>
NT2 MXXGeY5kfGmxbjDBd5NigQ>? M{nFXFQxOMLizsznM41t MmG3NlQhcA>? NYXzfYd2e2mpbnnmbYNidnSueTDk[YNz\WG|ZYOgRoNtNTJibHX2[Yw> Ml\5NlI1Pjl7NUK=
CHO NUnLRlhJTnWwY4Tpc44hSXO|YYm= M2fsclIvPcLizsznM41t M3LsT|E5KGhxNjDk NEi2XohqdmS3Y3XzxsBx\XK|aYP0[Y5k\SCxZjDjbJJwdW:|b33lJIRidWGpZR?= NF\Uc|MzOjJ|MEG5OS=>
Jurkat MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGS5NVgxNTFyMNMg{txoN22u NG\JfXYzPCCq MXPhdpJme3S|IITo[UBk\WyuIHP5Z4xmKGG2IITo[UBIOiCyaHHz[S=> MkTvNlIzOjN|M{K=
Jurkat NVS5VVJSTnWwY4Tpc44hSXO|YYm= MXuzNOKh|rypL33s NUHGb|NYOjRiaB?= MWHpcoNz\WG|ZYOgeIhmKHC{b4TlbY4hdGW4ZXzzJI9nKGO7Y3zpcpMhTDNuIFGgZY5lKEJz MXSyNlIzOzN|Mh?=
Jurkat NHW4TGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\aSVAuOTBywrFOwIcwdWx? NE\sXVEzPCCq MnvKbY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyJJdqfGhiYX6gTWM2OCC4YXz1[UBw\iBzMEFOwIcwdUx? M{XLO|IzOjJ|M{Oy
Jurkat NIPtUFZHfW6ldHnvckBCe3OjeR?= MVyzNOKh|rypL33s MYiyOEBp MWXpcoNz\WG|ZYOgeIhmKGWoZnXjeEBw\iCyeXPubYRqd26nIH;uJJBpd3OyaH;yfYxifGmxbjDs[ZZmdHNib3[gbIl{fG:wZTDINmEvYA>? MWOyNlIzOzN|Mh?=
U2OS EGFPnls M{OyfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXX6U4JtOC1{wrFOwIcwdWx? MmC1NlQhcA>? MYXpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 NETQ[2gzOThzMUCwOy=>
U2OS KuEnls NHvidHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fvR|AuOsLizsznM41t M1\NXlI1KGh? M{DyO4lvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> MVGyNVgyOTByNx?=
MCF-7 NWDNUXFzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVGwMVQxOCEQvF2= Mm\IO|IhcA>? M4HPXGxEPTB;MUWxMljDqM7:TR?= M3rOWVIyPzB|Mkmx
MCF-7/Adr  M4XuVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH71T|YxNTRyMDFOwG0> NYjtfG56PzJiaB?= MUjMR|UxRTV6LkZCpO69VcLi NYDYd5NYOjF5MEOyPVE>
WI-38 MUDGeY5kfGmxbjDBd5NigQ>? NWH1b2RxOC92MD:4NQKBkc7:Zz;tcOKh M1;VPVMhcA>? NYfxfYVHcW6mdXPld{BiKGOxbnPlcpRz[XSrb36t[IVx\W6mZX70JIlv[3KnYYPlJIlvKHSqZTDNUkBnemWzdXXuZ5nDqA>? NFnZeJMzOTV7OU[xNi=>
hBMSC NX\yOVI3TnWwY4Tpc44hSXO|YYm= MljhNE81OC96MPMAje69\y:vbNMg MofFN{Bp NXPmOopbcW6mdXPld{BiKGOxbnPlcpRz[XSrb36t[IVx\W6mZX70JIlv[3KnYYPlJIlvKHSqZTDNUkBnemWzdXXuZ5nDqA>? NX3ldJZ1OjF3OUm2NVI>
NCI-H23 M17mOWZ2dmO2aX;uJGF{e2G7 NX73O29KOC92MD:4NQKBkc7:Zz;tcOKh NWfINI86OyCq MlG5bY5lfWOnczDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IHnuZ5Jm[XOnIHnuJJRp\SCPTjDmdoVyfWWwY4pCpC=> NVfoVIw5OjF3OUm2NVI>
A-549 NYrFWHdITnWwY4Tpc44hSXO|YYm= NI\FTWkxNzRyL{iw5qCK|rypL33sxsA> NX\PTnlZOyCq NXLNZnlFcW6mdXPld{BiKGOxbnPlcpRz[XSrb36t[IVx\W6mZX70JIlv[3KnYYPlJIlvKHSqZTDNUkBnemWzdXXuZ5nDqA>? M4HN[VIyPTl7NkGy
PBL  MWfGeY5kfGmxbjDBd5NigQ>? MWGwM|QxNzhy4pEJ{txoN22uwrC= MYqzJIg> Mnv3bY5lfWOnczDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IHnuZ5Jm[XOnIHnuJJRp\SCPTjDmdoVyfWWwY4pCpC=> NVfEeGxLOjF3OUm2NVI>
pol β −/− M3qyN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXywMlI2NTJyMNMg{txoN22u NWrlNJFIOjUEoHi= NYKwRXhO\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JJdqfGhiaX7jdoVie2mwZzDjc45k\W62cnH0bY9ve8Li NWDtdZFbOjF{NUG5OFQ>
pol β +/+ MnOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWOwMlI2NTJyMNMg{txoN22u NWfLdYxuOjUEoHi= NUm3RmRR\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JJdqfGhiaX7jdoVie2mwZzDjc45k\W62cnH0bY9ve8Li MnLPNlEzPTF7NES=
pol β −/− NVnI[GlwTnWwY4Tpc44hSXO|YYm= NUnJUWF2OC1{LkWg{txoN22u M1;DVVIhcA>? M1;vT4NifXOnczDEUmEh\GGvYXfl MmDtNlEzPTF7NES=
pol β +/+ MUnGeY5kfGmxbjDBd5NigQ>? NETUS40xNTJwNTFOwIcwdWx? NEfOZnAzKGh? MWPjZZV{\XNiRF7BJIRidWGpZR?= M3\Nd|IyOjVzOUS0
pol β −/− M1y2Z2Z2dmO2aX;uJGF{e2G7 M3fZelAuPSEQvHevcYw> MX20PEBp NXrRW49P[2G3c3XzJI1q[3KxboXjcIV2eyCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueIx6 MYCyNVI2OTl2NB?=
pol β +/+ MmnpSpVv[3Srb36gRZN{[Xl? NH\ETFAxNTVizsznM41t NG\MWnI1QCCq NUnmNHdF[2G3c3XzJI1q[3KxboXjcIV2eyCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueIx6 M{C0TFIyOjVzOUS0
TK6  MlfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\lUnFqOjVvMUWwJO69\y:vbB?= NVfNUXZRQTZiaB?= MXjpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 MVuyNVA5OTR6Nx?=
TK6  sLUC+Apn1 MkOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYGxW2lzOjVvMUWwJO69\y:vbB?= MX[5OkBp MofRbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> NXnPc5c6OjFyOEG0PFc>
TK6 sAPE1+Apn1 M3fWZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\3Nm1EOjVvMUWwJO69\y:vbB?= MmHVPVYhcA>? NVeyOFIze2mpbnnmbYNidnSueTDpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 NWPZdJFMOjFyOEG0PFc>
HCT116 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkC3NlUuOTVyIN88[{9udA>? Mn7QPVYhcA>? NXnleZZCcW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? NUHLZYVYOjFyOEG0PFc>
HCT116 sLUC+Apn1 M{L5NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fBV|I2NTF3MDFOwIcwdWx? NVm5U|FoQTZiaB?= MXTpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 NEm4PFczOTB6MUS4Oy=>
HCT116 sAPE1+Apn1 MkHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3iclRIOjVvMUWwJO69\y:vbB?= MnzmPVYhcA>? M4nWfJNq\26rZnnjZY51dHliaX7obYJqfHNiY3XscEBoem:5dHig[I9{\SCmZYDlcoRmdnSueR?= M3LyWVIyODhzNEi3

... Click to View More Cell Line Experimental Data

In vivo Day 7 post-Bleomycin sulfate, CD45+ cells in BALf in NOX-/- is 1.7-fold > WT, 57% of which are Mf that decreases by 67% in WT and 83% in NOX-/- by Day 21. [5]

Protocol

Cell Research:

[4]

+ Expand
  • Cell lines: ADIPO-P2 cells
  • Concentrations: 2.5 μg/mL
  • Incubation Time: 30 minutes
  • Method:

    ADIPO-P2 cells are grown in D-MEM high glucose medium supplemented with 20% fetal calf serum, penicillin (100 U/mL) and streptomycin (100 μg/mL) at 37 °C and 5% CO2 atmosphere. Cells are cultured as monolayer in TC25 Corning flasks containing 1.5 × 105 cells/mL. For each experiment, two flasks are set up, one for the control and one for the treated culture. During the log phase of growth ADIPO-P2 cells are treated with a 30 minutes pulse of 2.5 μg/mL of Bleomycin sulfate. Control cultures are set up in parallel but not exposed to Bleomycin sulfate. Time of exposure and concentration of Bleomycin sulfate are chosen according to previous studies carried out in our laboratory with mammalian cells exposed to Bleomycin sulfate. At the end of the pulse treatment with Bleomycin sulfate, the cells are washed twice with Hank's balanced salt solution and kept in culture with fresh culture medium until harvesting. Cells are continuously maintained in culture during 5 passages or subcultures after treatment. Subcultivation is carried out whenever the cultures became confluent (approximately 4 × 105 cells/mL of culture medium). To estimate cell growth, at the time of subcultivation cells are collected by trypsinization, an aliquot of about 200 μL stained with 0.4% trypan blue, and the number of viable cells is determined. Cells are then suspended in fresh culture medium and dispensed into new culture flasks containing 1 × 105 cells/mL to continue growing. The rest of the cells is discarded or dispensed in another flask for cytogenetic analysis, which is performed at 18 hours and 10 days after the end of treatments. To analyze chromosomal aberrations, colchicine (0.1 μg/mL) is added to cell cultures during the last 3 hours of culture. Chromosome preparations are made following standard procedures. After harvesting, cells are hypotonically shocked, fixed in methanol:acetic acid (3:1), spread onto glass slides and processed for PNA-FISH. Two independent experiments are carried out.


    (Only for Reference)
Animal Research:

[7]

+ Expand
  • Animal Models: CD-1 mice
  • Formulation: Saline
  • Dosages: 5 mg/kg, 2 ml/kg
  • Administration: Administered via i.t.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL warmed (66.11 mM)
Water 100 mg/mL (66.11 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
Saline
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 1512.62
Formula

C55H85N17O25S4

CAS No. 9041-93-4
Storage powder
Synonyms NSC125066

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02166463 Recruiting Classical Hodgkin Lymphoma|Stage IIB Hodgkin Lymphoma|Stage IIIB Hodgkin Lymphoma|Stage IVA Hodgkin Lymphoma|Stage IVB Hodgkin Lymphoma National Cancer Institute (NCI) March 2015 Phase 3
NCT02582697 Recruiting Germ Cell Tumor University of Sydney|Australian and New Zealand Urogenital and Prostate Cancer Trials Group|Cambridge University Hospitals NHS Foundation Trust|Cancer Trials Ireland|Childrens Oncology Group|Dana-Farber Cancer Institute|University of Southern California February 2014 Phase 3
NCT01390584 Recruiting Lymphoma Eastern Cooperative Oncology Group|National Cancer Institute (NCI) April 2012 Phase 2
NCT01132807 Active, not recruiting Lymphoma Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) May 2010 Phase 2
NCT01042522 Recruiting Ovarian Granulosa Cell Tumor|Ovarian Gynandroblastoma|Ovarian Sertoli-Leydig Cell Tumor|Ovarian Sex Cord Tumor With Annular Tubules|Ovarian Sex Cord-Stromal Tumor|Ovarian Sex Cord-Stromal Tumor of Mixed or Unclassified Cell Types|Ovarian Steroid Cell Tumor Gynecologic Oncology Group|National Cancer Institute (NCI) February 2010 Phase 2
NCT01026220 Active, not recruiting Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma|Stage III Childhood Hodgkin Lymphoma|Stage IV Childhood Hodgkin Lymphoma Childrens Oncology Group|National Cancer Institute (NCI) December 2009 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How about the strength of Bleomycin Sulfate(S1214) in terms of Units/mg?

  • Answer:

    Our S1214 Bleomycin Sulfate is 1500 Units/mg.

  • Question 2:

    what is the ratio between bleomycin A2 and bleomycin B2 in your product?

  • Answer:

    The content of Bleomycin A2 and Bleomycin B2 is 62% and 29% respectively.

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

Tags: buy Bleomycin Sulfate | Bleomycin Sulfate ic50 | Bleomycin Sulfate price | Bleomycin Sulfate cost | Bleomycin Sulfate solubility dmso | Bleomycin Sulfate purchase | Bleomycin Sulfate manufacturer | Bleomycin Sulfate research buy | Bleomycin Sulfate order | Bleomycin Sulfate mouse | Bleomycin Sulfate chemical structure | Bleomycin Sulfate mw | Bleomycin Sulfate molecular weight | Bleomycin Sulfate datasheet | Bleomycin Sulfate supplier | Bleomycin Sulfate in vitro | Bleomycin Sulfate cell line | Bleomycin Sulfate concentration | Bleomycin Sulfate nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID